iRadimed (IRMD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.46
- Estimate
- $0.44
- Surprise
- +4.5%
- Revenue (period 2026-06-30)
- $20.5M
- Score at report (before → after)
- 5.4 → 5.6/10
Revenue source: xbrl.
How the report landed
iRadimed (IRMD) beat the $0.44 estimate with diluted EPS of $0.46 — a clear 4.5% upside surprise. TrendMatrix's engine moved from Sell (5.4/10) to Hold at 5.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IRMD Hold at 5.7/10.
3 of the last 4 quarters beat the estimate; this quarter's +4.5% surprise compares with a +7.6% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system
- Concentration risk — Supplier: single-source suppliers
- Expensive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $82.22
- Price target
- $100.30
- Stop
- $78.97
- Upside to target
- +22.0%
- Reward-to-risk
- 4.0:1
The stock trades at 45.9× trailing but 34.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 23 — a level conventionally read as oversold; trading volume is running 2.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
IRMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.05B
- P/E (fwd)
- 34.1
- P/E (ttm)
- 45.9
- 52-week range
- $67.84–$107.90
- Off 52-week high
- 23.8%
- RSI (14)
- 23
- Volume vs avg
- 2.69×
- Score today
- 5.7/10